Levy T(1), Marchand L(1), Stroobant V(2), Pilotte L(2), Van den Eynde B(2), Rodriguez F(1), Delfourne E(3). Author information:
(1)Université Paul Sabatier, UMR CNRS 5068, Laboratoire de Synthèse et
Physicochimie de Molécules d'Intérêt Biologique, 118 Route de Narbonne, 31062
Toulouse Cédex 9, France.
(2)Ludwig Cancer Research Ltd (Brussels Branch) & de Duve Institute (Tumor
Immunology & Antigen Processing Group), Avenue Hippocrate 74 (UCL B1.7403)
B-1200, Bruxelles, Belgium.
(3)Université Paul Sabatier, UMR CNRS 5068, Laboratoire de Synthèse et
Physicochimie de Molécules d'Intérêt Biologique, 118 Route de Narbonne, 31062
Toulouse Cédex 9, France. Electronic address: [Email]
Indoleamine 2,3-dioxygenase (IDO1) and tryptophane 2,3-dioxygenase (TDO) are two heme-containing enzymes which catalyze the conversion of tryptophan to N-formylkynurenine. Both enzymes are well establish therapeutic targets as important factors in the tumor immune evasion mechanism. A number of analogues of the marine pyrroloquinoline alkaloids tsitsikammamines or wakayin have been synthesized, two of them were synthesized using an original method to build the bispyrroloquinone framework. All the derivatives were evaluated in a cellular assay for their capacity to inhibit the enzymes. Six compounds have shown a significant potency on HEK 293-EBNA cell lines expressing hIDO1 or hTDO.
OUR JOURNALS
Having over 250 Research scholars worldwide and more than 400 articles online with open access.
